15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Kiniksa Pharmaceuticals Ltd, 7 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $60.00 to $75.00, so the covering firms are broadly aligned. The average target of $68.00 sits 14% below the current $79.15. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.31 next quarter toward $1.70 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Moderate Buy
Strong Buy00%
Buy7100%
Hold00%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Kiniksa Pharmaceuticals Ltd.
As of Jul, 7 of 7 firms rate KNSA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
KNSA EPS & revenue forecast
EPS · NEXT QUARTER
$0.31
Range $0.29 – $0.32 · 4 analysts · +34% YoY
Next period, 4 analysts expect Kiniksa Pharmaceuticals Ltd to earn $0.31 a share (range $0.29 – $0.32), versus $0.23 a year earlier. Full-year consensus is $1.16, growing to $1.70 the year after.
REVENUE · NEXT QUARTER
$241.3M
Range $236.9M – $245.0M · 4 analysts · +33% YoY
Revenue is expected to reach $241.3M (range $236.9M – $245.0M), +33.4% year-over-year. Full-year consensus is $940.1M, rising to $1.1B next year.
Top analysts covering Kiniksa Pharmaceuticals Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KNSA.
#1
Anupam Rama
JP Morgan · Rank #62
Buy
$40.00-49.5% to target
Overall win rate
46%
+ Follow
#2
David Nierengarten
Wedbush · Rank #115
Buy
$72.00-9.0% to target
Overall win rate
41%
+ Follow
#3
Roger Song
Jefferies
Buy
$71.00-10.3% to target
Coverage
—
+ Follow
#4
EF
Eva Fortea Verdejo
Wells Fargo
Buy
$74.00-6.5% to target
Coverage
—
+ Follow
#5
Geoff Meacham
Citigroup
Buy
$60.00-24.2% to target
Coverage
—
+ Follow
KNSA stock forecast FAQ
What is KNSA's average 12-month price target?+
The 7 analysts with a live target average $68.00 for Kiniksa Pharmaceuticals Ltd over the next 12 months, ranging from a $75.00 high to a $60.00 low.
Is KNSA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 7 analyst ratings, 7 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for KNSA?+
The Street-high target is $75.00 (Goldman Sachs), and the Street-low is $60.00 (Citigroup). The average of all 7 active targets is $68.00.
How many Wall Street analysts cover KNSA?+
7 analysts have an active rating on Kiniksa Pharmaceuticals Ltd, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering KNSA?+
Among analysts who currently cover KNSA, Anupam Rama of JP Morgan has the strongest overall Quantellect track record (Rank #62). Their current call is Buy with a $40.00 target.
What is Kiniksa Pharmaceuticals Ltd's projected EPS for next quarter?+
The consensus estimate is $0.31 per share (range $0.29 – $0.32) across 4 analysts. Full-year EPS is projected at $1.16, rising to $1.70 the following year.
How much revenue is Kiniksa Pharmaceuticals Ltd expected to report next quarter?+
Consensus revenue is $241.3M (range $236.9M – $245.0M). Full-year revenue is projected at $940.1M, growing to $1.1B next year.
Have analysts been upgrading or downgrading KNSA lately?+
As of Jul, 7 of 7 firms rate KNSA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KNSA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
